Apeloa Pharmaceutical (000739.SZ)'s subsidiary obtains the registration certificate for Cefdinir granules for oral suspension.

Apeloa Pharmaceutical (000739.SZ) announced that its wholly-owned subsidiary Zhejiang Puluo Jutai Pharmaceutical Co., Ltd. has received the "Drug Registration Certificate" for Cefdinir Granules for Oral Suspension (1.5g; 3.0g) issued by the State Food and Drug Administration. The announcement indicates that Cefdinir Granules for Oral Suspension belong to the third generation of oral cephalosporin antibiotics and are suitable for treating mild to moderate infections in pediatric patients caused by sensitive strains of designated microorganisms under the following conditions: Acute bacterial otitis media caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae (only strains sensitive to penicillin), and Moraxella catarrhalis (including beta-lactamase-producing strains). Pharyngitis/tonsillitis caused by Streptococcus pyogenes. Simple skin and skin tissue infections caused by Staphylococcus aureus (including beta-lactamase-producing strains) and Streptococcus pyogenes.